Press release
Intellia Therapeutics, Inc. (NASDAQ: NTLA) Investor Alert: Deadline in Lawsuit on April 14, 2025
A Deadline is coming up on April 14, 2025 in the lawsuit for certain investors in Intellia Therapeutics, Inc. (NASDAQ: NTLA).
Investors who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) have certain options and there are strict and short deadlines running. Deadline: April 14, 2025. NASDAQ: NTLA stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the District of Massachusetts the plaintiff alleges on behalf of purchasers of Intellia Therapeutics, Inc. (NASDAQ: NTLA) common shares between July 30, 2024 to January 8, 2025, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between July 30, 2024 to January 8, 2025, the defendants made false and/or misleading statements and/or failed to disclose that the defendants created the false impression that they possessed reliable information pertaining to the viability of NTLA-3001's development and eventual marketing, if approved, that Intellia's optimistic reports of timelines, including dosing and future studies of the drug, fell short of reality; the NTLA program was not viable or sustainable for Intellia because viral-based editing programs remained expensive and inefficient in comparison to then-existing non-viral delivery methods, that Intellia was not equipped to timely dose patients with NTLA-3001, maintain the drug's research and development, or even to maintain its full staff in light of the existing scientific landscape surrounding viral-based editing drugs, and that even if NTLA-3001 proved successful, the use of viral-based editing drugs is costly, inefficient, and poor mitigators of adverse effects in patients.
Those who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Intellia Therapeutics, Inc. (NASDAQ: NTLA) Investor Alert: Deadline in Lawsuit on April 14, 2025 here
News-ID: 3961555 • Views: …
More Releases from Shareholders Foundation, Inc.
Lawsuit Alert: Investors who lost money with shares of Molina Healthcare, Inc. ( …
An investor, who purchased shares of Molina Healthcare, Inc. (NYSE: MOH), filed a lawsuit over alleged violations of Federal Securities Laws by Molina Healthcare, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Molina Healthcare, Inc. (NYSE: MOH) have certain options and for certain investors are short and strict deadlines running. Deadline: December 02, 2025. NYSE: MOH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
CTO Realty Growth, Inc. (NYSE: CTO) Long Term Investor Alert: Investigation of p …
An investigation on behalf of current long-term investors in shares of CTO Realty Growth, Inc. (NYSE: CTO) concerning potential breaches of fiduciary duties by certain directors and officers of CTO Realty Growth, Inc. was announced.
Investors who are current long term investors in CTO Realty Growth, Inc. (NYSE: CTO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a…
Lawsuit filed for Investors who lost money with shares of Marex Group plc (NASDA …
An investor, who purchased shares of Marex Group plc (NASDAQ: MRX), filed a lawsuit in the U.S. District Court for the Southern District of New York over alleged violations of Federal Securities Laws by Marex Group plc in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of Marex Group plc (NASDAQ: MRX) between May 16, 2024 and August 5, 2025, have certain options…
LifeMD, Inc. (NASDAQ: LFMD) Investor Alert: Deadline in Lawsuit on October 27, 2 …
A deadline is coming up on October 27, 2025 in the lawsuit filed for certain investors of LifeMD, Inc. (NASDAQ: LFMD) over alleged securities laws violations by LifeMD, Inc.
Investors who purchased shares of LifeMD, Inc. (NASDAQ: LFMD) have certain options and there are strict and short deadlines running. Deadline: October 27, 2025. LifeMD, Inc. (NASDAQ: LFMD) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for NTLA
CRISPR Therapies Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, The …
(Albany, USA) DelveInsight's "CRISPR Therapies Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the CRISPR Therapies market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.
The CRISPR therapies landscape is witnessing rapid growth and is powered by cutting-edge research…
Long-Term Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) shou …
An investigation was announced on behalf of current long-term investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) concerning potential breaches of fiduciary duties by certain directors of Intellia Therapeutics, Inc.
Investors who are current long term investors in Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long…
CRISPR Therapies Pipeline: Revolutionizing Treatment with 25+ Innovators Driving …
The CRISPR therapies landscape is witnessing rapid growth and is powered by cutting-edge research and transformative innovations. Pioneering companies like Tango Therapeutics, KSQ Therapeutics, CRISPR Therapeutics, Emendo Biotherapeutics, and Beam Therapeutics are leading the charge-reshaping therapeutic approaches and unlocking new possibilities in genetic medicine. With their groundbreaking advancements, these leaders are paving the way for a future where CRISPR-based treatments offer renewed hope and lasting impact for patients worldwide.
DelveInsight's "CRISPR…
Hereditary Angioedema Pipeline: Over 20 Leading Companies Driving Innovation wit …
The Hereditary Angioedema market is rapidly advancing and is fueled by groundbreaking research and innovative therapies from companies such as BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, and BioMarin Pharmaceutical. These industry pioneers are transforming treatment strategies and redefining the future of Hereditary Angioedema, bringing new hope to patients worldwide.
DelveInsight's "Hereditary Angioedema Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Hereditary Angioedema market. The report covers…
Cardiac Amyloidosis Pipeline: Advancing Innovation with 20+ Companies Developing …
The Cardiac Amyloidosis market is rapidly advancing and is fueled by groundbreaking research and innovative therapies from companies such as Eidos Therapeutics, Intellia Therapeutics, Novo Nordisk, Alnylam Pharmaceuticals, and Precision Biosciences. These industry pioneers are transforming treatment strategies and redefining the future of Cardiac Amyloidosis, bringing new hope to patients worldwide.
DelveInsight's "Cardiac Amyloidosis Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Cardiac Amyloidosis market.…
Investors who lost money with shares of Intellia Therapeutics, Inc. (NASDAQ: NTL …
An investor, who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA), filed a lawsuit over alleged violations of Federal Securities Laws by Intellia Therapeutics, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) have certain options and for certain investors are short and strict deadlines running. Deadline: April 14, 2025. NASDAQ: NTLA investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
